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1101-46 First Human Experience With the ABT-578 Eluting 
Phosphorylcholine Polymer Stent: A Serial Volumetric 
Intravascular Ultrasound Analysis From the PREFER 
Trial
Ryota Sakurai, Yoichiro Hongo, John Ormiston, Robert J. Whitbourn, Ian Meredith, 
Yasuhiro Honda, Paul G. Yock, Peter J. Fitzgerald, The PREFER Trial Investigators, 
Stanford University, Stanford, CA, Green Lane Hospital, Auckland, New Zealand
Background: ABT-578, an analog of rapamycin, is an anti-proliferative agent with prom-
ising preclinical study results. PREFER is a multicenter, non-randomized, single-arm,
feasibility trial of the ABT-578 eluting phosphorylcholine-coated BiodivYsio® (Abbott Vas-
cular Devices, Redwood City, CA) stent which enrolled 11 cases with de novo human cor-
onary lesions. The aim of this substudy was to evaluate the impact of this new drug-
eluting stent on both stented segment and stent edges.
Methods: Serial 3-D IVUS analysis (baseline and 3-month follow-up) was available in 9
out of 11 patients (one case was excluded due to low IVUS image quality; the other due
to additional dilatation with a non-study stent). Minimum lumen area (LA) and mean
areas for lumen, plaque (PA), stent (SA), vessel (VA) and neointima (NIA) were mea-
sured over the stented and the stent edge (both 5 mm proximal and distal adjacent to the
stent) segments.
Results: At baseline, neither significant plaque protrusion / thrombus nor edge dissec-
tion was detected. At follow-up, no late incomplete stent apposition was observed. Mean
NIA was 0.17 ± 0.32 mm2, and %NIA (100*mean NIA/mean SA) was 2.11 ± 3.96%.
Table shows serial changes in quantitative IVUS parameters.
Conclusion: Preliminary analysis of the initial human experience with the ABT-578 elut-
ing phosphorylcholine-coated stent showed no apparent adverse vessel response. The
amount of neointimal proliferation was minimum. Further studies will be needed to con-
firm these favorable observations. 
1101-63 Impact of Preinterventional Lesion Calcification on 
Neointimal Hyperplasia Following Sirolimus-Eluting 
Stent Implantation: An Intravascular Ultrasound 
Analysis
Hideaki Kaneda, Tomomi Koizumi, Junya Ako, Yasuhiro Honda, Mitsuyasu Terashima, 
Yoshihisa Shimada, Yoshihiro Morino, Paul G. Yock, Martin B. Leon, Jeffrey W. Moses, 
Peter J. Fitzgerald, The SIRIUS Investigators, Stanford University, Stanford, CA, Lenox 
Hill Hospital, New York, NY
Background: Although the negative impact of lesion calcification on stent expansion is
well known, the effect of calcification on neointimal hyperplasia (IH) following sirolimus-
eluting stent (SES) implantation is not well characterized.
Methods: Eighty-two patients who underwent SES (n=45) or bare metal stent (n=37)
implantation and preinterventional IVUS were enrolled in this substudy from the overall
SIRIUS population. Lesions were divided into calcified (defined as calcific deposits at
minimum lumen area cross section), or non-calcified. Stent, lumen, IH (stent-lumen) area
were measured at baseline and 8 month follow-up.
Results: Overall, acute lumen area gain tended to be less in calcified lesion (5.19±2.38
vs. 6.06±2.43mm2, P=0.13), resulting in smaller stent area (7.90±2.60 vs.8.70±2.56mm2,
P=0.19). There was a significant interaction between calcification and stent type on IH
suppression (Figure). However, multiple logistic regression analysis including stent type,
stent area at baseline, and plaque type showed that stent type was the only predictor for
target lesion revascularization or binary angiographic restenosis.
Conclusion: The treatment effect between sirolimus and control in reducing restenosis
remained constant, irrespective of lesion characteristics. Despite less optimal acute
results in calcified lesions, SES suppressed IH effectively. 
1101-64 Six-Month Intracoronary Ultrasound Findings Following 
Sirolimus-Eluting Stents for the Treatment of 
Restenosis-Prone Coronary Lesions
José Suárez de Lezo, Alfonso Medina, Miguel Romero, Manuel Pan, José Segura, 
Antonio Delgado, Djordje Pavlovic, Isabel Ureña, Enrique Hernández, Juan Herrador, 
Federico Segura, Francisco Melián, Reina Sofía Hospital, Córdoba, Spain, Dr. Negrín 
Hospital, Las Palmas de Gran Canaria, Spain
Background: Drug-eluting stents are promising. However, follow-up information is still
limited. Intravascular ultrasound (IVUS) is a unique tool is evaluating in situ late results.
Methods: We describe the follow-up IVUS findings obtained from 102 patients with coro-
nary lesions prone to restenosis who had been treated with sirolimus-eluting stents
(SES). Lesions were considered at risk for restenosis because of the following reasons:
in-stent restenosis, major bifurcation lesion, long-diffuse stenosis, or chronic total occlu-
sion. Sixty-two patients had more than 1 risk condition for restenosis. The mean age was
60±10 years. All patients had six-month angiographic and IVUS evaluation. Motorized
IVUS pull-back study of the treated segment was always performed. Proximal and distal
references were interrogated at 1 cm from the stent borders. Intrastent IVUS-measure-
ments were also performed. Results: Qualitatively, we observed focal non-stent apposi-
tion in 11 patients and a bulge or minor aneurysm formation in 2. Eleven patients (11%)
showed focal restenosis. In the remaining 91 patients, the stent was covered with a fine
lining. In addition, the intima was thicker at the edges showing compensatory vessel
enlargement. The table summarizes the quantitative results.
Conclusion: These findings show that adequate healing of restenosis-prone lesions
occurs in most patients. However, focal restenosis may develop. A favorable remodeling
is observed at the edges.
1101-65 Predictors of Edge Stenosis Following Sirolimus-
Eluting Stent Deployment: A Quantitative Intravascular 
Ultrasound Analysis From the SIRIUS Trial
Ryota Sakurai, Junya Ako, Shinjo Sonoda, Hideaki Kaneda, Yoshihiro Morino, Mitsuyasu 
Terashima, Ali Hassan, Paul G. Yock, Martin B. Leon, Jeffrey W. Moses, Peter J. 
Fitzgerald, Yasuhiro Honda, Stanford University, Stanford, CA
Background: While sirolimus-eluting stents (SES) have substantially reduced instent
restenosis, less efficacy at stent edges has been reported in the SIRIUS trial, a multi-
center, randomized, prospective clinical trial comparing the sirolimus-eluting Bx VELOCI-
TYTM stent to bare metal stents.
Methods: Angiographic and IVUS data were obtained from SIRIUS. To investigate possi-
ble determinants of peri-stent edge stenosis (defined as diameter stenosis greater than
50% either proximal or distal to the stent) at follow-up, baseline IVUS parameters were
analyzed in 172 edges of 92 SES.
Results: Of these, 6 edges in 6 SES had edge stenosis at 8-month follow-up. Quantita-
tive IVUS results are shown in the table.
Conclusion: The IVUS measurements of maximum stent area (SA) and edge SA com-
pared to reference suggest that overexpansion (not detected by angio balloon / artery
TLR (n=8) No TLR (n=32)
Radiation failure (%) 71 54
Lesion length (mm) 41.4±33.1 25.8±14.5
Number of stents 2.8±1.9 1.6±1.0
Residual edge lesion (%) 25 19
Reference EEM area (mm2) 9.86±6.30 9.47±4.60
Reference lumen area (mm2) 7.31±4.14 6.54±3.44
Minimum stent area (mm2) 4.32±1.98 4.71±1.68
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ratio) may contribute to edge stenosis. The greater reference residual plaque area by
IVUS in this group also suggests that inadequate stent coverage contributes to edge
stenosis. Optimal deployment techniques, including both inside and outside the stent,
may further improve efficacy of SES.
1101-66 Intimal Hyperplasia Thickness Is Independent of Stent 
Size in Paclitaxel-Coated Stents: A Serial Intravascular 
Ultrasound Analysis From the Asian Paclitaxel-Eluting 
Stent Clinical Trial
Esteban Escolar, Gary S. Mintz, Myeong-Ki Hong, Cheol Whan Lee, Jae-Joong Kim, 
Neal E. Fearnot, Seong-Wook Park, Seung-Jung Park, Neil J. Weissman, Washington 
Hospital Center, Washington, DC, Asan Medical Center, Seoul, Democratic People's 
Republic of Korea
Background.Intravascular ultrasound (IVUS) studies have shown that IH thickness is
independent of bare metal stent size. This study determined whether intimal hyperplasia
(IH) thickness within nonpolymeric paclitaxel-coated stents is dependent on stent size.
Methods. IVUS was performed post-stent implantation and at 6-months follow-up in 81
patients, 55 of which were randomized to the nonpolymeric paclitaxel-coated stent: 27 to
3.1 mcg/mm2 (High dose) and 28 to 1.28 mcg/mm2 (low dose). Stent, lumen, and IH
cross-sectional area (CSA) and IH thickness were measured every 1mm over the length
of the stent for a total of 810 slices. Maximum IH CSA and thickness and mean IH CSA
and thickness over the length of the stent were calculated.
Results. Overall, maximum IH CSA measured 2.15±1.58mm2, mean IH CSA measured
0.99±0.91mm2, maximum IH thickness measured 0.49±0.33mm, and mean IH thickness
measured 0.33±0.21mm. There was a weak correlation between IH CSA vs stent CSA
(r=0.196, p<0.0001), but no correlation between IH thickness vs stent CSA (r=0.052,
p=0.138) on a per slice basis or between maximum IH CSA vs stent CSA (r=0.259,
p=0.056) or maximum IH thickness vs stent CSA (r=0.07, p=0.6) on a per stent basis.
The results were similar when high and low dose patients were analyzed separately on a
per slice basis: (1) IH CSA vs Stent CSA (r=0.252, p<0.0001, and r=0.153, p=0.0013)
and (2) IH thickness vs Stent CSA (r=0.126, p=0.015, and r=0.002, p=0.96).
Conclusions. IH thickness is independent of stent size in drug-eluting stents, similar to
bare metal stents.
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1102-47 Important Species Differences of Sirolimus, Paclitaxel, 
and Tacrolimus on Porcine and Human Coronary 
Smooth Muscle and Endothelial Cells
Kai Pinkernell, Christian Valina, Eckhard Alt, Tulane University, School of Medicine, New 
Orleans, LA
Background: Implantation of drug coated stents shows clinical efficacy for the preven-
tion of restenosis, but large animal studies have not shown any long term benefit with the
use of Sirolimus (SIR) and Paclitaxel (PAC). Despite this the possible interspecies differ-
ences have not been investigated. Methods: Porcine (p) and human (h) smooth muscle
(SMC) and endothelial cells (EC) were serum deprived for 48h until addition of drugs.
Cells were counted after 72h of exposure to SIR, PAC or Tacrolimus (TAC) by means of a
CASY cell counter on the basis of the resistance measurement principle. Cell viability
and size was determined simultaneously. Results: hSMC and hEC were generally more
susceptible to growth inhibition than porcine cells (maximum differences seen with SMC).
More than a 90% reduction in cell due to cytotoxicity could be seen for hSMC at 10µM for
SIR and PAC compared to 75µM TAC. pSMC showed only a 80% reduction at 75µM for
SIR and PAC and a 40% reduction with TAC. SIR showed the most pronounced effect
with 99% reduction in cell count starting at 50µM compared to 100µM for pSMC. Conclu-
sion: Toxicity and cell growth inhibition shows remarkable species differences at concen-
trations which are easily exceeded in the stent vicinity in vivo (100 µM). This partially
explains the different results of re-endothelialization and reduction of in-stent restenosis
with drug coated stents in swine and humans and shows the problems regarding the pre-
diction of outcomes in human trials on the basis of animal data.
1102-48 Inhibitory Effect of E5555, an Orally Active Thrombin 
Receptor Antagonist, on Intimal Hyperplasia Following 
Balloon Injury
Toshiyuki Matsuoka, Motoji Kogushi, Tsutomu Kawata, Akifumi Kimura, Ken-ichi Chiba, 
Takashi Musha, Hiroko Kobayashi, Tetsuya Kawahara, Shuichi Suzuki, Akiharu Kajiwara, 
Ieharu Hishinuma, Clinical Research Center, Eisai Co., Ltd., Tokyo, Japan, Tsukuba 
Research Laboratories, Eisai Co., Ltd., Tsukuba, Japan
Background: Thrombin plays an important role in the development of restenosis and
atherosclerosis after percutaneous coronary intervention via protease-activated recep-
tors (PARs). Thrombin receptor (PAR-1), one of the PARs, mediates a variety of cellular
actions of thrombin such as smooth muscle cell (SMC) proliferation and platelet aggrega-
tion. We succeeded in developing an orally active PAR-1 antagonist, E5555. The aims of
this study is to clarify the in vitro profile of E5555 and to evaluate the effect of E5555 on
intimal hyperplasia after balloon injury of the rat carotid artery.
Methods: 1) Human platelet membranes were incubated with [3H]-high-affinity thrombin
receptor activating peptide (TRAP) in the presence of E5555. 2) Effects of E5555 on rat
SMC proliferation induced by thrombin (0.1 units/mL), basic fibroblast growth factor (3 ng/
mL) or platelet-derived growth factor (30 ng/mL) was evaluated by colorimetric assay
using MTT. 3) E5555 (10 and 30 mg/kg) or vehicle was given orally to male rats once a
day for 16 days. On day 3, carotid artery lesion was induced by balloon denudation. Four-
teen days after the surgery, the injured vessels were harvested and elastia-van Gieson’s
staining was performed.
Results: 1) E5555 inhibited binding of [3H]-high-affinity TRAP to PAR-1 in human platelet
membranes in a concentration-dependent manner with an IC50 value of 0.019 µM (n=6).
2) E5555 inhibited rat SMC proliferation induced by thrombin with an IC50 value of 0.16
µM (n=4), but did not inhibit that induced by basic fibroblast growth factor or platelet-
derived growth factor. 3) The area of neointima in the vehicle-treated group (n=23) was
0.132±0.010 mm2 (mean±SEM), while that in the group treated with E5555 at 10 mg/kg
(n=24) and 30 mg/kg (n=24) were 0.116±0.007 mm2 (ns vs. vehicle) and 0.078±0.009
mm2 (p<0.001), respectively. The ratio of neointimal to medial area was significantly
decreased in the group treated with E5555 at 30 mg/kg (0.866±0.092 vs. 1.404±0.091 in
vehicle, p<0.001) without affecting the medial area.
Conclusion: E5555, a potent and orally active PAR-1 antagonist, may be beneficial for
the treatment of restenosis after percutaneous coronary intervention.
1102-49 A New Peptide to Block Interaction of Leukocyte 
Integrin MAC-1 With Fibrinogen Reduces Intimal 
Thickening in Mice
Zhongmin Zhou, Marc S. Penn, Tatiana P. Ugarova, Kai Wang, Cleveland Clinic 
Foundation, Cleveland, OH
Background: The interaction between fibrinogen and leukocyte integrin MAC-1
 
medi-
ates a range of adhesive reactions during vascular response to injury, and plays a key
role in pathogenesis of restenosis. We developed a new peptide which duplicates the
sequence in fibrinogen and which binds MAC-1 integrin, and investigated its effect on
intimal thickening after vascular injury in mice. Methods: Carotid artery wire injuries were
induced in ten CD57 mice of age 8 to 12 weeks, 0.2 mg/mouse of peptide or saline were
given intraperitoneally at 0, 2, 4, and 6 days, mice were sacrificed at 21 days after injury,
and morphometric analysis was carried out. Results: Neointimal area was significantly
reduced by over 60% in peptide treated mice compared with saline control (0.009 ±0.006
mm2 vs 0.022 ± 0.012 mm2, p < 0.05), reduction of intima/media ratio was also observed
in peptide versus saline group (0.374 ± 0.206 vs 0.795 ± 0.368, p <0.05) (table). conclu-
sion: blockade of interaction between fibrinogen and leukocyte mac-1
 
by a new peptide
suppresses neointimal thickening in mice.
table. morphometric data 
Edge Stenosis No Edge Stenosis P-Value
Reference MLA (mm2) 4.7±2.3 6.5±2.3 0.06
Reference Residual Plaque (%) 60.5±9.0 49.1±11.5 0.03
Maximum SA / Reference MLA 1.8±0.2 1.5±0.5 0.03
Edge SA / Reference MLA 1.5±0.3 1.2±0.3 0.03
Maximum Pressure (atm) 15.4±3.2 16.9±2.7 NS
Balloon / Artery Ratio 0.9±0.1 1.0±0.1 NS
MLA: Minimum Lumen Area
SA: Stent Area
NS: Not Significant
